Table 2.
Characteristics of patients hospitalized for VT and PE, and of the related hospital stay between January (Week 1) and October (Week 40) 2020 compared with the corresponding time period in 2017–2019, according to the type of diagnosis. Bold: p-value < 0.05.
| Deep venous thrombosis as primary diagnosis |
Pulmonary embolism as primary diagnosis |
Deep venous thrombosis as associated diagnosis |
Pulmonary embolism as associated diagnosis |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year | 2017–2019 | 2020 | p | 2017–2019 | 2020 | p | 2017–2019 | 2020 | p | 2017–2019 | 2020 | p |
| Patients' characteristics | ||||||||||||
| Women, % | 52.8 | 52.4 | 0.50 | 52.6 | 52.0 | 0.05 | 48.2 | 46.6 | <0.01 | 50.6 | 47.3 | <0.01 |
| Age, mean (std) | 65.6 (19.4) | 64.7 (19.9) | <0.01 | 69.0 (16.8) | 68.5 (17.2) | <0.01 | 67.0 (18.8) | 66.9 (18.6) | 0.18 | 70.3 (16.0) | 69.4 (16.1) | <0.01 |
| 0–65 years old, % | 41.6 | 42.9 | 0.03 | 33.9 | 35.1 | <0.01 | 38.0 | 37.9 | 0.79 | 31.1 | 33.6 | <0.01 |
| Charlson index score, % | 0.02 | <0.01 | <0.01 | <0.01 | ||||||||
| • 0–1 | 42.5 | 43.5 | 49.8 | 50.5 | 38.1 | 38.2 | 35.2 | 41.5 | ||||
| • 2–3 | 27.6 | 26.2 | 27.5 | 27.7 | 31.9 | 32.4 | 33.9 | 31.6 | ||||
| • 4+ | 29.9 | 30.3 | 22.7 | 21.8 | 30.0 | 29.4 | 30.8 | 26.9 | ||||
| Hospitalization or official ‘long-term disease’ status in the five years preceding the index hospitalizationa | ||||||||||||
| • Pulmonary embolism | 3.6 | 2.7 | <0.01 | 10.0 | 9.3 | <0.01 | 2.6 | 1.7 | <0.01 | 13.4 | 9.6 | <0.01 |
| • Venous thromboembolism | 16.9 | 17.8 | 0.04 | 12.2 | 10.9 | <0.01 | 11.4 | 9.8 | <0.01 | 16.0 | 11.4 | <0.01 |
| • Coagulation abnormalities | 9.8 | 10.1 | 0.42 | 6.2 | 6.3 | 0.52 | 7.8 | 7.6 | 0.07 | 6.4 | 5.3 | <0.01 |
| • Stroke | 5.8 | 5.9 | 0.52 | 5.6 | 5.7 | 0.36 | 8.1 | 8.4 | 0.03 | 9.7 | 9.4 | 0.36 |
| • Ischemic heart disease | 15.5 | 14.8 | 0.08 | 12.9 | 12.2 | <0.01 | 16.8 | 17.2 | 0.06 | 15.4 | 14.1 | <0.01 |
| • Heart failure | 13.7 | 13.2 | 0.21 | 14.0 | 13.4 | 0.01 | 15.4 | 15.6 | 0.13 | 16.6 | 14.2 | <0.01 |
| Treatment delivery in the year preceding the index hospitalizationa | ||||||||||||
| • Antihypertensives | 53.8 | 52.6 | 0.03 | 53.7 | 51.1 | <0.01 | 57.3 | 57.3 | 0.77 | 58.1 | 54.9 | <0.01 |
| • Antidiabetics | 15.7 | 16.2 | 0.27 | 12.0 | 11.9 | 0.69 | 17.6 | 18.7 | <0.01 | 15.6 | 16.0 | 0.20 |
| • Lipid-lowering medications | 26.7 | 25.2 | <0.01 | 27.0 | 24.4 | <0.01 | 27.7 | 27.9 | 0.20 | 28.4 | 26.6 | <0.01 |
| • Oral anticoagulants | 11.0 | 10.5 | 0.15 | 7.3 | 5.9 | <0.01 | 14.9 | 14.7 | 0.16 | 14.8 | 11.1 | <0.01 |
| • Heparin | 5.6 | 4.7 | <0.01 | 2.6 | 2.1 | <0.01 | 6.2 | 4.8 | <0.01 | 5.2 | 3.5 | <0.01 |
| • Antiplatelets | 24.5 | 23.2 | <0.01 | 22.3 | 20.9 | <0.01 | 25.1 | 25.1 | 0.96 | 24.2 | 23.0 | <0.01 |
| Disease management and hospital stay | ||||||||||||
| Length of stay, mean (std) | 7.1 (9.0) | 7.2 (9.9) | <0.01 | 9.3 (9.4) | 9.0 (9.0) | <0.01 | 16.1 (16.8) | 16.5 (17.3) | <0.01 | 17.7 (18.2) | 18.0 (17.9) | <0.01 |
| Admitted to intensive care unit, %b | 4.4 | 4.8 | 0.09 | 26.7 | 26.1 | 0.02 | 16.9 | 19.8 | <0.01 | 23.4 | 28.0 | <0.01 |
| In-patient mortality, % | 1.7 | 1.8 | 0.53 | 4.8 | 4.9 | 0.51 | 7.3 | 7.8 | <0.01 | 15.3 | 16.1 | <0.01 |
| 90-day post-admission mortality, %b | 7.6 | 8.3 | 0.06 | 7.2 | 8.0 | <0.01 | 12.0 | 11.9 | 0.82 | 15.4 | 15.0 | 0.27 |
std: standard deviation; p: 2020 vs. 2017–2019.
a
Available for patients without linkage error (i.e., 99% of patients).
b
Available for patients affiliated to France's general healthcare insurance scheme (i.e., 77% of included patients).